Compare HUN & BRVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | BRVE |
|---|---|---|
| Founded | 1970 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2004 | 2026 |
| Metric | HUN | BRVE |
|---|---|---|
| Price | $9.58 | $21.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $10.29 | ★ $45.25 |
| AVG Volume (30 Days) | ★ 2.8M | 305.0K |
| Earning Date | 11-02-2026 | 11-19-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,683,000,000.00 | N/A |
| Revenue This Year | $8.36 | N/A |
| Revenue Next Year | $2.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.30 | $17.86 |
| 52 Week High | $16.09 | $32.00 |
| Indicator | HUN | BRVE |
|---|---|---|
| Relative Strength Index (RSI) | 64.70 | 48.33 |
| Support Level | $9.42 | $17.93 |
| Resistance Level | $9.99 | $29.86 |
| Average True Range (ATR) | 0.37 | 1.25 |
| MACD | 0.15 | 0.43 |
| Stochastic Oscillator | 98.12 | 80.69 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).